首页> 外文会议>International Peptide Symposium;European Peptide Symposium >Tumor selective accumulation of PNA-oligomers conjugated to a somatostatin receptor affine peptide
【24h】

Tumor selective accumulation of PNA-oligomers conjugated to a somatostatin receptor affine peptide

机译:与生长抑制素受体染肽缀合的PNA-低聚体的肿瘤选择性积累

获取原文

摘要

Peptide nucleic acids(PNAs)are synthetic DNA analogs in which the sugar phosphate backbone is substituted by neutral amide backbone linkages.Due to this modification,PNAs are achiral and uncharged DNA mimics.Their N-(2-amino-ethyl)-glycine backbone is stable to degradation by proteases as well as nucleases.The purine or pyrimidine bases are linked to the backbone via a methylene carbonyl linker resulting in a geometry similar to the geometry of 'natural' nucleic acids.The hybridization affinity of PNA-oligomers to complementary DNA sequences is higher than the hybridization affinity between analogous DNA oligomers.Consequently,PNA has attracted major attention because of its potential to act as an active component for diagnostic as well as pharmaceutical applications.Due to these properties PNA oligomers are an appropriate choice for pretargeting and in vivo hybridization techniques.However,as with other drugs of high molecular mass,the delivery of PNA,involving passage through the cell membrane,appears to be a general problem.This limited uptake of PNA into cells is still the major obstacle for applying PNA as an antisense agent in clinical applications.
机译:肽核酸(PNA)是合成DNA类似物,其中糖磷酸盐骨架被中性酰胺骨架键取代。为该改性,PNA是成立的和不带电的DNA模拟物。N-(2-氨基 - 乙基) - 甘甘蓝骨髓骨架通过蛋白酶和核酸酶来降解稳定。嘌呤或嘧啶碱通过亚甲基羰基接头连接到骨架上,导致类似于“天然”核酸的几何形状的几何形状。PNA-低聚物的杂交亲和力互补DNA sequences is higher than the hybridization affinity between analogous DNA oligomers.Consequently,PNA has attracted major attention because of its potential to act as an active component for diagnostic as well as pharmaceutical applications.Due to these properties PNA oligomers are an appropriate choice for pretargeting并且在体内杂交技术中。然而,与其他高分子质量的其他药物一样,PCNA的递送,涉及通过CEL的通过L膜似乎是一般问题。将PNA的限制为细胞仍然是临床应用中施用PNA作为反义药剂的主要障碍。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号